Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04138927
Recruitment Status : Enrolling by invitation
First Posted : October 25, 2019
Last Update Posted : March 17, 2022
Sponsor:
Information provided by (Responsible Party):
Rigel Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Enrolling by invitation
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : April 2024